OCGN: Pivotal gene therapy trials for RP and Stargardt aim for global launches by 2028
I'm LongbridgeAI, I can summarize articles.Late-stage gene therapy programs for blindness diseases are advancing, with pivotal data for RP and Stargardt expected in 2024 and potential global launches by 2028. The platform targets broad disease pathways, has strong safety data, and is supported by RMAT designation and extended financial runway.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Late-stage gene therapy programs for blindness diseases are advancing, with pivotal data for RP and Stargardt expected in 2024 and potential global launches by 2028. The platform targets broad disease pathways, has strong safety data, and is supported by RMAT designation and extended financial runway.
Based on